You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Acute Graft versus Host Disease

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Steroid-refractory Acute Graft-versus-host Disease Trial (MC0518, BAT)

Not yet recruiting
  • Steroid-refractory Acute Graft-versus-host Disease
  • MC0518
  • BAT
  • (no location specified)
Oct 4, 2023

Acute GVHD, Hematopoietic and Lymphoid System Tumor Trial in Seattle (Fecal Microbiota Transplantation Capsule, Placebo)

Not yet recruiting
  • Acute Graft Versus Host Disease
  • Hematopoietic and Lymphoid System Neoplasm
  • Fecal Microbiota Transplantation Capsule
  • Placebo
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Sep 6, 2023

Acute GVHD Trial (Itolizumab, Methylprednisolone)

Not yet recruiting
  • Acute Graft Versus Host Disease
  • (no location specified)
Apr 10, 2023

Acute GVHD, Gastrointestinal Tract Acute GVHD, Severe Gastrointestinal Tract Acute GVHD Trial in Los Angeles (Fecal Microbiota

Not yet recruiting
  • Acute Graft Versus Host Disease
  • +3 more
  • Fecal Microbiota Transplantation Capsule
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Sep 16, 2022

Acute Graft Versus Host Disease

Not yet recruiting
  • GVHD,Acute
  • blood sample
  • Detroit, Michigan
    Henry Ford Health System
Jan 30, 2023

Acute GVHD, Hematopoietic and Lymphoid System Tumor Trial in Duarte (Cholestyramine, Leflunomide, Steroid Therapy)

Recruiting
  • Acute Graft Versus Host Disease
  • Hematopoietic and Lymphoid System Neoplasm
  • Duarte, California
    City of Hope Medical Center
Jan 5, 2023

Acute Graft-versus-host Disease Trial in Duarte (GDC-8264)

Recruiting
  • Acute Graft-versus-host Disease
  • Duarte, California
    City of Hope National Medical Center
Jan 12, 2023

Steroid-refractory Acute Graft-versus-Host Disease, Treatment-refractory Acute Graft-versus-Host Disease Trial in United States

Completed
  • Steroid-refractory Acute Graft-versus-Host Disease
  • Treatment-refractory Acute Graft-versus-Host Disease
  • Neihulizumab (ALTB-168)
  • Duarte, California
  • +12 more
Jan 17, 2023

Acute GVHD Trial in Kansas City (MSCTC-0010 Dose Escalation)

Recruiting
  • Acute Graft Versus Host Disease
  • MSCTC-0010 Dose Escalation
  • Kansas City, Kansas
    Kansas University Cancer Center
Jan 30, 2023

Acute GVHD Trial (MTX, Corticosteroid)

Not yet recruiting
  • Acute Graft Versus Host Disease
  • (no location specified)
Jun 26, 2023

GVHD Trial in Tampa (Cultured Treg cells)

Completed
  • Graft Versus Host Disease
  • Cultured Treg cells
  • Tampa, Florida
    H Lee Moffitt Cancer Center
Nov 2, 2022

Transplant-Related Disorder Trial in Tianjin (Ruxolitinib)

Recruiting
  • Transplant-Related Disorder
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Jan 28, 2023

GVHD, Postbiotics, Butyrate Trial in Seoul (sodium butyrate)

Recruiting
  • Graft Versus Host Disease
  • +2 more
  • sodium butyrate
  • Seoul, Korea, Republic of
    Soonchunhyang University Seoul Hospital
Apr 11, 2023

Transplant-Related Disorder Trial (Ruxolitinib)

Not yet recruiting
  • Transplant-Related Disorder
  • (no location specified)
Oct 25, 2022

Graft Vs Host Disease Trial in Vandoeuvre Les Nancy (Uvadex, Steroids)

Not yet recruiting
  • Graft Vs Host Disease
  • Vandoeuvre Les Nancy, France
    CHRU de Nancy
Nov 10, 2023

Acute Graft-versus-Host Disease

Active, not recruiting
  • Acute Graft-versus-Host Disease
  • Allogeneic Stem Cell Transplant
  • Blood samples
  • Columbus, Ohio
    Ohio State University Medical Center
Apr 18, 2022

Hematopoietic Stem Cell Transplantation, Acute GVHD, Acute Myeloid Leukemia Trial in United States (CD24Fc, Placebo,

Terminated
Has Results
  • Hematopoietic Stem Cell Transplantation
  • +4 more
  • Duarte, California
  • +3 more
Oct 18, 2022

Graft Vs Host Disease, Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease Trial in Boston (Exercise, Attention

Recruiting
  • Graft Vs Host Disease
  • +2 more
  • Exercise
  • Attention control
  • Boston, Massachusetts
  • +1 more
Nov 28, 2022

Hematopoietic and Lymphoid Cell Tumor, Steroid Refractory GVHD Trial in Houston (Cellular Therapy, Ruxolitinib)

Recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • Steroid Refractory Graft Versus Host Disease
  • Houston, Texas
    M D Anderson Cancer Center
Jul 9, 2022

Therapeutic Drug Monitoring and Serum TNFa Levels in Pediatric

Completed
  • Acute Graft-versus-host Disease
    • Trieste, Italy
      IRCCS Burlo Garofolo
    Apr 11, 2023

    Gastro-Intestinal Acute GVHD (GI-aGVHD) Trial in Cleveland (Fecal Microbiota Transplantation (FMT))

    Withdrawn
    • Gastro-Intestinal Acute Graft Versus Host Disease (GI-aGVHD)
    • Fecal Microbiota Transplantation (FMT)
    • Cleveland, Ohio
      Case Medical Center, University Hospitals Seidman Cancer Center,
    Jul 1, 2022

    GVHD, GVHD, Acute-graft-versus-host Disease Trial in Canada, United States (Itolizumab, EQ001 Placebo)

    Recruiting
    • Graft Versus Host Disease
    • +4 more
    • Itolizumab
    • EQ001 Placebo
    • Duarte, California
    • +5 more
    Jul 5, 2022

    Dendritic Cells in Acute or Chronic Skin Graft Versus Host

    Recruiting
    • Acute Graft-versus-host Disease
    • +3 more
    • Skin punch biopsy
    • Peripheral blood draw
    • Saint Louis, Missouri
      Washington University School of Medicine
    May 31, 2022

    Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease, Solid Organ Transplant Trial in Cincinnati (Ruxolitinib)

    Recruiting
    • Acute-graft-versus-host Disease
    • +2 more
    • Cincinnati, Ohio
      Cincinnati Children's Hospital Medical Center
    Mar 31, 2022

    GVHD, Acute Trial (CYP-001 (Cymerus mesenchymoangioblast-derived mesenchymal stem cells; MCA-derived MSCs), Placebo,

    Not yet recruiting
    • Graft Versus Host Disease, Acute
    • CYP-001 (Cymerus mesenchymoangioblast-derived mesenchymal stem cells; MCA-derived MSCs)
    • +2 more
    • (no location specified)
    Dec 6, 2022